Further characterization of signalling events bridging EGF and Dorsal/NF-κB signalling could yield valuable insight into the regulation of the therapeutically important NF-κB family of proteins and broaden our understanding of how neoplasms which have attained EGF-family mutations interface with the body’s immune surveillance mechanisms. The gene discussed is EGF; the disease is neoplasm.